India, Aug. 26 -- Biohaven Ltd. (BHVN), a biopharmaceutical company, on Wednesday announced a global licensing agreement with SK Biopharmaceuticals Co., Ltd. (326030.KS).
Under the agreement, SK Biopharmaceuticals will obtain worldwide rights to Biohaven's Kv7 drug platform, led by opakalim, an experimental treatment for focal epilepsy.
The company will receive $400 million in near-term cash, plus up to $150 million in development and regulatory payments and royalties on U.S. sales.
SK Biopharmaceuticals will take over future Kv7 development costs and certain obligations of up to $245 million.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
The company said that the topline results from the RISE3 tr...